News - ACELLMED

Establishing scientific cooperation with the M. Skłodowska-Curie National Research Institute of Oncology Gliwice Branch.

We are pleased to announce that on 08/11/2022 a Scientific Cooperation Agreement was signed between the M. Skłodowska-Curie National Research Institute of Oncology Gliwice Branch and the consortium: Acellmed Sp. z o.o. and Silesian Park of Medical Technology Kardio-Med Silesia. The scientific cooperation will consist in verifying the therapeutic activity and specificity of action of the anti-acute myeloid leukemia (AML) drug being developed by the Acellmed – ŚPTM Kardio-Med Silesia consortium on leukemic cells of AML patients being treated at the M. Skłodowska-Curie National Research Institute of Oncology Gliwice Branch.
…

7 December 2022acellmedNews

Acellmed among the finalists of this year’s EEC Start-up Challenge!

Nearly 150 applications were submitted to the prestigious Start-up Challenge 2022 competition, organized within the framework of 14th European Economic Congress. As a result, the most interesting start-ups, divided into five contest categories, were selected. The best 15, who qualified for the semi-finals, presented their work to a broad audience during the European Economic Congress,…

17 May 2022acellmedNews

Start-up Challenge 2022

We are pleased to announce that Acellmed has been qualified as one of the 15 start-ups to the semi-finals of the Start-up Challenge 2022 competition and will be presented during the XIV European Economic Congress on 25-27.04.2022. We will present our company in the category HEALTH & BIOTECHNOLOGY – Medicine, health, medical technology, pharmacy, biotechnology.…

14 April 2022acellmedNews